Drugs / ALLO-316
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04696731 | Feb 2021 → Jan 2030 expected | clear cell renal carcinoma | Allogene Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04696731 ↗ |
| Action | Deplete | “ALLO-316 is an allogeneic chimeric antigen receptor (CAR) T-cell product that targets CD70-expressing ccRCC and resists immune rejection by targeting and eliminating patients'...” PMID 42447427 ↗ Jul 2026 |
| Modality | Cell therapy | “ALLO-316 is an allogeneic CAR T cell therapy” NCT04696731 ↗ |
| Target | CD70 | “targeting CD70” NCT04696731 ↗ |